In conclusion, this study provides a comprehensive analysis of the microRNA‐494‐3p/ATF3/α‐SMA signalling axis in rSjP40‐mediated inhibition of LX‐2 cell activation, highlighting ATF3 as a potential therapeutic target for liver fibrosis. This evidence concerns the gene ATF3 and Hepatic fibrosis.